The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …

Background AVERROES, a randomized controlled trial in high-risk patients with atrial
fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

Aims Real-world data on treatment persistence, safety and effectiveness of non-Vitamin K
antagonist oral anticoagulants (NOACs) play an important role in the assessment of risks …

Introduction Apixaban has been shown to be superior to warfarin in patients with non-
valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in …

Background Apixaban is a non–vitamin K oral anticoagulant approved for prevention of
stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current …

Background Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually
be detected only by long-term continuous monitoring with pacemakers or defibrillators …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …